Significant Correlation between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana

Journal of Infectious Diseases

Volumn 215, Issue 1, 2017, Pages 34-41

  Harris, Vanessa C ^a,b   Armah, George ^e   Fuentes, Susana ^c   Korpela, Katri E ^f   Parashar, Umesh ^g   Victor, John C ^h   Tate, Jacqueline ^g   De Weerth, Carolina ^d   Giaquinto, Carlo ⁱ   Wiersinga, Willem Joost ^b   Lewis, Kristen D C ^b,j   De Vos, Willem M ^c,f  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e University of Ghana   (Ghana)

^f UNIVERSITY OF HELSINKI   (Finland)

^g NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^h PATH   (United States)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j BILL AND MELINDA GATES FOUNDATION   (United States)

more..

Author keywords

intestinal microbiome; mucosal immunity; rotavirus vaccine

Indexed keywords

IMMUNOGLOBULIN A; LIVE VACCINE; ROTAVIRUS VACCINE; VIRUS ANTIBODY;

BACTERIUM; BACTEROIDETES; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; CLINICAL TRIAL; FECES; FEMALE; GASTROENTERITIS; GENETICS; GHANA; HUMAN; IMMUNOLOGY; INFANT; INTESTINE FLORA; ISOLATION AND PURIFICATION; MALE; MICROARRAY ANALYSIS; MICROBIOLOGY; MUCOSAL IMMUNITY; PREGNANCY; ROTAVIRUS; ROTAVIRUS INFECTION; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; STREPTOCOCCUS EQUINUS; VIROLOGY;

ANTIBODIES, VIRAL; BACTERIA; BACTEROIDETES; CASE-CONTROL STUDIES; FECES; FEMALE; GASTROENTERITIS; GASTROINTESTINAL MICROBIOME; GHANA; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFANT; MALE; MICROARRAY ANALYSIS; PREGNANCY; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; RURAL POPULATION; STREPTOCOCCUS BOVIS; VACCINES, ATTENUATED;

EID: 85021857835     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw518     Document Type: Article

References (41)

1. Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirusassociated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136-41.
2. Fischer Walker CL, Black RE. Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. BMC Public Health 2011; 11(Suppl 3):S16.
3. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14.
4. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
5. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
6. Baar-Zeev N, Kapanda L, Tate JE, et al. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infect Dis 2015; 15:422-8.
7. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
8. Linhares AC, Velázquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
9. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63.
10. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
11. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200(suppl 1):S28-38.
12. Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunology 2015; 8:1-17.
13. Emperador DM, Velasquez DE, Estivariz CF, et al. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. Clin Infect Dis 2016; 62:150-6.
14. Moon S-S, Groome MJ, Velasquez DE, et al. Prevaccination rotavirus serum IgG and IgA are associated with lower immunogenicity of live, oral human rotavirus vaccine in South African infants. Clin Infect Dis 2016; 62:157-65.
15. Chilengi R, Simuyandi M, Beach L, et al. Association of maternal immunity with rotavirus vaccine immunogenicity in Zambian infants. PLoS One 2016; 11: e0150100.
16. Nordgren J, Sharma S, Bucardo F, et al. Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin Infect Dis 2014; 59:1567-73.
17. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995; 13:310-2.
18. Ruiz-Palacios GM, Guerrero ML, Bautista-Márquez A, et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics 2007; 120:e253-61.
19. Ghana Statistical Service, Ghana Health Service, and ICF International. Ghana demographic and health survey, 2014. Rockville, MD: GSS, GHS, and ICF International, 2015. Available at: https://dhsprogram.com/pubs/pdf/FR307/FR307.pdf. Accessed 20 June 2016.
20. Armah G, Lewis KDC, Cortese MM, et al. A randomized controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants. J Infect Dis 2016; 213:1678-85.
21. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013; 208:284-94.
22. de Weerth C, Fuentes S, Puylaert P, De Vos WM. Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics 2014; 131: e550-8.
23. Zijlmans MAC, Korpela K, Riksen-Walraven JM, De Vos WM, de Weerth C. Maternal prenatal stress is associated with the infant intestinal microbiota. Psychoneuroendocrinology 2015; 53:233-45.
24. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1997; 16:381-7.
25. Ward RL, Bernstein DI, Shukla R, et al. Protection of adults rechallenged with a human rotavirus. J Infect Dis 1990; 161:440-5.
26. Tedjo DI, Jonkers DMAE, Savelkoul PH, et al. The effect of sampling and storage on the fecal microbiota composition in healthy and diseased subjects. PLoS One 2015; 10:e0126685.
27. Rajilić-Stojanović M, Heilig HGHJ, Molenaar D, et al. Development and application of the Human Intestinal Tract Chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 2009; 11:1736-51.
28. Salonen A, Nikkilä J, Jalanka-Tuovinen J, et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 2010; 81:127-34.
29. Claesson MJ, O'Sullivan O, Wang Q, et al. Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One 2009; 4:e6669.
30. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473:174-80.
31. Haegeman B, Hamelin JEROM, Moriarty J, Neal P, Dushoff J, Weitz JS. Robust estimation of microbial diversity in theory and in practice. ISME J 2013; 7:1092-101.
32. Leps J, Smilauer P. Multivariate analysis of ecological data using CANOCO. Cambridge, United Kingdom: Cambridge University Press, 2003.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing on JSTOR. J R Stat Soc Ser B 1995; 57:289-300.
34. The R Project for Statistical Computing. 2016. https://www.r-project.org.
35. Vatanen T, Kostic AD, d'Hennezel E, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 2016; 165:842-53.
36. Hofstad T, Sveen K, Dahlén G. Chemical composition, serological reactivity and endotoxicity of lipopolysaccharides extracted in different ways from Bacteroides fragilis, Bacteroides melaninogenicus and Bacteroides oralis. Acta Pathol Microbiol Scand B 1977; 85:262-70.
37. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001; 7:167-202.
38. Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS. Modulating the innate immune response by combinatorial engineering of endotoxin. PNAS 2013; 110:1464-9.
39. Jans C, Meile L, Lacroix C, Stevens MJA. Genomics, evolution, and molecular epidemiology of the Streptococcus bovis/Streptococcus equinus complex (SBSEC). Infect Genet Evol 2015; 33:419-36.
40. Jones MK, Watanabe M, Zhu S, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 2014; 346:755-9.
41. Payne DC, Currier RL, Staat MA, et al. Epidemiologic association between FUT2 secretor status and severe rotavirus gastroenteritis in children in the United States. JAMA Pediatr 2015; 169:1040.